Brachytherapy Gains Momentum With 12-Year Survival Data Released At AUA
This article was originally published in The Gray Sheet
Executive Summary
Favorable long-term efficacy data continue to fuel rapid growth in prostate cancer brachytherapy, which physicians predict will be the treatment of choice in 25% of cases in 2000.